검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Cabozantinib |
Overview Company | Academic and Community Cancer Research United |
Overview Modality | ADC |
Overview Target | FRα |
Overview Indication | Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeted agents, including epidermal growth factor receptor, anaplastic lymphoma kinase, BCR-ABL, vascular endothelial growth factor receptor |
MoA Biomarker | biomarkers in several malignancies; however, their role in patients receiving avelumab maintenance for advanc |
PK/PD Half-life | 55 h |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Dog, Mouse, Rat, Rabbit |
Toxicology Animal (cat.) | Mouse, Rat, Dog |
Toxicology Major finding | thrombocytopenia, hypophosphatemia, and hyperbilirubinemia |
Clinical Primary efficacy | ORR 59% |
Clinical ORR | 59% |
Clinical Result source | ClinicalTrials.gov NCT03729245 |
Clinical Data Tier / Score | A · 34 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 6일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Cabozantinib |
Overview Company | Academic and Community Cancer Research United |
Overview Modality | ADC |
Overview Target | FRα |
Overview Indication | Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeted agents, including epidermal growth factor receptor, anaplastic lymphoma kinase, BCR-ABL, vascular endothelial growth factor receptor |
MoA Biomarker | biomarkers in several malignancies; however, their role in patients receiving avelumab maintenance for advanc |
PK/PD Half-life | 55 h |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Dog, Mouse, Rat, Rabbit |
Toxicology Animal (cat.) | Mouse, Rat, Dog |
Toxicology Major finding | thrombocytopenia, hypophosphatemia, and hyperbilirubinemia |
Clinical Primary efficacy | ORR 59% |
Clinical ORR | 59% |
Clinical Result source | ClinicalTrials.gov NCT03729245 |
Clinical Data Tier / Score | A · 34 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 6일 (8일 전) |
추천 비교
추천 비교